Benzinga NRx Pharma Stock Jumps After FDA Signals Path To NDA For Ketamine Depression Drug
The FDA signals its willingness to review NRx Pharmaceuticals' NRX-100 NDA, boosting optimism around its depression treatment. Importance Rank: 1 read more
The FDA signals its willingness to review NRx Pharmaceuticals' NRX-100 NDA, boosting optimism around its depression treatment. Importance Rank: 1 read more